Navigating the Platelet Puzzle: Clozapine Treatment in Parkinson's Disease - The Dilemma of Continuation
Arielle Silbersweig,Cristina M. Pritchett,Claudio S. Bondulich,Adriana P. Hermida
DOI: https://doi.org/10.1016/j.jagp.2024.01.148
IF: 7.996
2024-02-22
American Journal of Geriatric Psychiatry
Abstract:Introduction Parkinson's disease is one of the most common neurodegenerative diseases, strongly affecting the well-being of patients and caregivers. Neuropsychiatric symptoms of Parkinson's disease include psychosis, dementia, depression, anxiety, REM sleep behavior disorder, and impulse control disorders. In patients with Parkinson's disease with distressing psychosis, pimavanserin, quetiapine, and clozapine can be used. Clozapine has fewer motor effects compared with other antipsychotic agents, though there are many side effects to consider. The most common side effects of clozapine are sialorrhea, constipation, and clozapine-induced gastrointestinal hypomotility. Some of the most dangerous are agranulocytosis, myocarditis, and cardiomyopathy. In addition to agranulocytosis, other hematologic side effects include neutropenia, leukocytosis, eosinophilia, thrombocytosis, and thrombocytopenia. Compared with data on clozapine induced leukopenia, the incidence, biological mechanism, and treatment options for clozapine induced thrombocytopenia are less well understood. We provide a case report on a patient in late life who has suffered from Parkinson's disease psychosis, on longstanding treatment with clozapine but recent development of thrombocytopenia. Methods A case report of the use of clozapine in treating psychosis in Parkinson's disease and potential thrombocytopenia along with a literature review of the subject will be presented. Results 85-year-old retired PhD male, living with his wife in a senior living community in Georgia, with a history of Parkinson's disease diagnosed 20 years ago, Parkinson's disease-related psychosis that started 10 years ago, dementia due to Parkinson's disease diagnosed 5 years ago, and REM sleep behavior disorder. Other past medical history includes prostate cancer, gradually worsening thrombocytopenia for the past 8 months, sialorrhea requiring Botox, constipation, and levodopa-induced dyskinesia. His medications are carbidopa-levodopa, clozapine, donepezil, desvenlafaxine succinate, rasagiline, and caffeine. He experiences bilateral tremor, bradykinesia, shuffling gait, masked facies, bradyphrenia, and hypophonia and is fully dependent for activities of daily living. His psychotic symptoms present as delusional jealousy and visual hallucinations of dogs and children, mostly at night. Initially, he tried multiple antipsychotics with insufficient response. He has been on clozapine for nearly 10 years with moderate efficacy, though he continues to have distressing delusions. His current dose is 62.5 mg daily. White blood cell and absolute neutrophil counts have been within normal limits. However, he has developed thrombocytopenia. Though his platelet counts were previously normal, they were 134,000/μL, 115, 000/μL, and 103,000/μL 8 months, 5 months, and 1 month ago respectively. He has had no symptoms of easy bleeding or bruising. He is continuing his current dose of clozapine with laboratory monitoring and referral to hematology to rule out other causes of thrombocytopenia. Conclusions The literature on clozapine induced thrombocytopenia is limited. There have been a handful of case reports on clozapine induced thrombocytopenia, including patients non-naïve to clozapine, along with a few studies and case series. The incidence of clozapine induced thrombocytopenia is variable but ranges from 0.083% to 8.2% in larger samples. Most cases occur within the first 18 weeks of clozapine initiation. Clozapine induced thrombocytopenia is usually transient and self-resolving, in most cases lasting under 13 weeks, though has been noted to last up to 40 months in one case report. One proposed biological mechanism is immune mediated due to a common side effect of eosinophilia. There is also a higher incidence of anemia in the first few years following clozapine initiation, demonstrating its potential to affect all three cell lines. It is important to document hematologic baselines before initiating clozapine treatment and to be aware of potential side effects in addition agranulocytosis. The manufacturer recommends discontinuing the drug when the platelet count falls below 100,000/μL, resuming therapy when the count returns to normal range, and permanently discontinuing if thrombocytopenia reoccurs. UK guidelines recommend that if the platelet count falls below 50,000/μL, clozapine should be discontinued, with monitoring frequency increased. If platelet counts remain over this limit and there are no side effects such as easy bleeding or bruising, it is reasonable to continue clozapine treatment and monitor for the period to pass. Especially in the geriatric population where falls and balance-related inj -Abstract Truncated-
psychiatry,geriatrics & gerontology,gerontology